Tuesday 19 December 2017 by Bonnie Corbett Company updates

New DirectBond – Valeant Pharmaceuticals International senior secured notes

The latest DirectBond is a multinational, specialty pharmaceutical and medical device company

valeant

Valeant Pharmaceuticals International, Inc. (Valeant) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices that are marketed in over 100 countries. Valeant is diverse in its sources of revenue primarily from its broad drug and medical device portfolio but also among the therapeutic classes and geographies the company serves. Valeant’s portfolio of products falls into three reportable segments: Bausch + Lomb/International, Branded Rx, and US Diversified Products.

Issued on 17 October 2017, the senior secured notes are available from USD10,000, with semi annual coupon payments at a fixed rate of 5.50%, and a final maturity date of 1 November 2025. 

The bond is available to wholesale investors only. For more information, please see the Valeant 2025 Factsheet

 

Get your free copy of The Benefits of Corporate Bonds eBook

Get a copy of The Benefits of Corporate Bonds eBook

Subscribe to The WIRE newsletter

Sign up to a free weekly newsletter to get the latest investment news.